

Xuefu Zhuyu Decoction combined with symptomatic supportive treatments for COPD

Patient or population: patients with COPD

Settings:

Intervention: Xuefu Zhuyu Decoction combined with symptomatic supportive treatments

Outcomes	Illustrative comparative risks* (95% CI)	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Control				
FEV1/FVC(%) - FEV1/FVC(%)⁻Total	The mean fev1/fvc(%) - fev1/fvc(%) ⁻ -total in the intervention groups was 4.12 higher (2.09 to 6.15 higher)		645 (10 studies)	⊕ ⊕ ⊕ ⊕ low ^{1,2}	
FEV1% - FEV1%⁻Total	The mean fev1% - fev1% ⁻ -total in the intervention groups was 7.33 higher (2.38 to 12.27 higher)		381 (6 studies)	⊕ ⊕ ⊕ ⊕ low ^{1,2}	
FEV1 - FEV1⁻Total	The mean fev1 - fev1 ⁻ -total in the intervention groups was 0.16 higher (0.06 to 0.26 higher)		604 (9 studies)	⊕ ⊕ ⊕ ⊕ low ^{1,2,3}	
P(O2) - P(O2)⁻Total	The mean p(o2) - p(o2) ⁻ -total in the intervention groups was 8.38 higher (4.88 to 11.88 higher)		413 (6 studies)	⊕ ⊕ ⊕ ⊕ low ^{1,2}	
P(CO2) - P(CO2)⁻Total	The mean p(co2) - p(co2) ⁻ -total in the intervention groups was 3.43 lower (5.57 to 1.28 lower)		413 (6 studies)	⊕ ⊕ ⊕ ⊕ low ^{1,2}	
Clinical efficacy rate - Clinical efficacy rate	Study population	RR 1.26	485 (8 studies)	⊕ ⊕ ⊕ ⊕ moderate ¹	
	746 per 1000 940 per 1000 (873 to 1000)				
	Moderate				
Adverse events	Study population	OR 0.19	290 (4 studies)	⊕ ⊕ ⊕ ⊕ very low ^{1,3}	
	14 per 1000 3 per 1000 (0 to 53)				
	Moderate				
	0 per 1000 0 per 1000 (0 to 0)				

D-dimer	The mean d-dimer in the intervention groups was 2.41 standard deviations lower (3.98 to 0.84 lower)	333 (5 studies)	⊕ ⊕ ⊕ ⊕ low ^{1,2}	SMD -2.41 (-3.98 to -0.84)
FIB	The mean fib in the intervention groups was 1.45 lower (2.16 to 0.74 lower)	270 (4 studies)	⊕ ⊕ ⊕ ⊕ low ^{1,2}	
PT	The mean pt in the intervention groups was 3.01 higher (2.51 to 3.52 higher)	183 (3 studies)	⊕ ⊕ ⊕ ⊕ moderate ^{1,2}	
APTT	The mean aptt in the intervention groups was 1.46 higher (1.15 lower to 4.07 higher)	273 (4 studies)	⊕ ⊕ ⊕ ⊕ very low ^{1,2,3}	

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio; **OR:** Odds ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ There are unclear risks on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment

² The outcome is heterogeneous

³ Real effects exceed the upper and lower bounds of the confidence interval